Brivaracetam: clinical use
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Brivaracetam: clinical use. Brivaracetam is a synaptic vesicle protein 2A (SV2A) ligand. Fully referenced neurology checklist.
Mode of action
- Brivaracetam is a synaptic vesicle protein 2A (SV2A) ligand
Indications
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Brivaracetam benefits over Levetiracetam
Locked: subscribe to see this section.
Brivaracetam conversion from Levetiracetam
Locked: subscribe to see this section.
References
- Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015; 56:1890-1898.
- Ben-Menachem E, Mameniškienė R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 2016; 87:314-323.
- Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2017; 58:255-262.
- Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure 2018; 61:98-103.
- Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018; 59:1549-1556.
- And 8 more. Subscribe to see the full list
